Molecular Templates, Inc. (MTEM)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 31.17 Million USD | -72.34% |
| 2022 | 112.68 Million USD | -11.07% |
| 2021 | 126.7 Million USD | 57.32% |
| 2020 | 80.53 Million USD | 13.16% |
| 2019 | 71.17 Million USD | 81.33% |
| 2018 | 39.25 Million USD | 199.59% |
| 2017 | 13.1 Million USD | 198.11% |
| 2016 | 4.39 Million USD | -65.73% |
| 2015 | 12.82 Million USD | -86.12% |
| 2014 | 92.37 Million USD | -27.6% |
| 2013 | 127.59 Million USD | 23.43% |
| 2012 | 103.37 Million USD | 475.8% |
| 2011 | 17.95 Million USD | 59.43% |
| 2010 | 11.26 Million USD | -56.74% |
| 2009 | 26.02 Million USD | 735.03% |
| 2008 | 3.11 Million USD | -49.94% |
| 2007 | 6.22 Million USD | -51.33% |
| 2006 | 12.79 Million USD | 0.49% |
| 2005 | 12.73 Million USD | -78.3% |
| 2004 | 58.68 Million USD | 15.15% |
| 2003 | 50.96 Million USD | 442.58% |
| 2002 | 9.39 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 19.58 Million USD | -7.83% |
| 2024 Q1 | 21.24 Million USD | -31.83% |
| 2023 Q3 | 37.26 Million USD | -15.68% |
| 2023 Q4 | 31.17 Million USD | -16.34% |
| 2023 FY | 31.17 Million USD | -72.34% |
| 2023 Q2 | 44.19 Million USD | -45.05% |
| 2023 Q1 | 80.41 Million USD | -28.63% |
| 2022 Q1 | 115.68 Million USD | -8.7% |
| 2022 Q4 | 112.68 Million USD | -1.58% |
| 2022 Q2 | 115.09 Million USD | -0.51% |
| 2022 FY | 112.68 Million USD | -11.07% |
| 2022 Q3 | 114.49 Million USD | -0.52% |
| 2021 Q1 | 143.41 Million USD | 78.08% |
| 2021 FY | 126.7 Million USD | 57.32% |
| 2021 Q3 | 145.82 Million USD | -1.04% |
| 2021 Q4 | 126.7 Million USD | -13.11% |
| 2021 Q2 | 147.35 Million USD | 2.75% |
| 2020 Q3 | 84.93 Million USD | -1.87% |
| 2020 Q4 | 80.53 Million USD | -5.18% |
| 2020 FY | 80.53 Million USD | 13.16% |
| 2020 Q2 | 86.55 Million USD | 12.44% |
| 2020 Q1 | 76.97 Million USD | 8.15% |
| 2019 Q2 | 41.88 Million USD | -5.8% |
| 2019 Q1 | 44.46 Million USD | 13.29% |
| 2019 Q3 | 40.14 Million USD | -4.16% |
| 2019 FY | 71.17 Million USD | 81.33% |
| 2019 Q4 | 71.17 Million USD | 77.29% |
| 2018 Q2 | 17.24 Million USD | 5.94% |
| 2018 Q4 | 39.25 Million USD | -14.24% |
| 2018 FY | 39.25 Million USD | 199.59% |
| 2018 Q1 | 16.27 Million USD | 24.21% |
| 2018 Q3 | 45.76 Million USD | 165.48% |
| 2017 Q4 | 13.1 Million USD | -10.49% |
| 2017 FY | 13.1 Million USD | 198.11% |
| 2017 Q3 | 14.63 Million USD | 268.34% |
| 2017 Q2 | 3.97 Million USD | -14.09% |
| 2017 Q1 | 4.62 Million USD | 5.26% |
| 2016 Q2 | 8.36 Million USD | 16.55% |
| 2016 Q1 | 7.17 Million USD | -44.02% |
| 2016 Q4 | 4.39 Million USD | -35.08% |
| 2016 FY | 4.39 Million USD | -65.73% |
| 2016 Q3 | 6.77 Million USD | -19.08% |
| 2015 FY | 12.82 Million USD | -86.12% |
| 2015 Q4 | 12.82 Million USD | -86.48% |
| 2015 Q3 | 94.85 Million USD | -5.29% |
| 2015 Q2 | 100.15 Million USD | -7.17% |
| 2015 Q1 | 107.89 Million USD | 16.81% |
| 2014 Q1 | 123.66 Million USD | -3.08% |
| 2014 FY | 92.37 Million USD | -27.6% |
| 2014 Q3 | 97.67 Million USD | -13.12% |
| 2014 Q2 | 112.42 Million USD | -9.09% |
| 2014 Q4 | 92.37 Million USD | -5.43% |
| 2013 Q1 | 135.68 Million USD | 31.26% |
| 2013 Q4 | 127.59 Million USD | 7.63% |
| 2013 Q3 | 118.54 Million USD | -8.61% |
| 2013 Q2 | 129.71 Million USD | -4.4% |
| 2013 FY | 127.59 Million USD | 23.43% |
| 2012 Q4 | 103.37 Million USD | -20.67% |
| 2012 FY | 103.37 Million USD | 475.8% |
| 2012 Q3 | 130.3 Million USD | -5.38% |
| 2012 Q2 | 137.71 Million USD | -17.61% |
| 2012 Q1 | 167.16 Million USD | 831.1% |
| 2011 Q3 | 17.42 Million USD | -13.99% |
| 2011 Q4 | 17.95 Million USD | 3.05% |
| 2011 Q1 | 19.31 Million USD | 71.53% |
| 2011 FY | 17.95 Million USD | 59.43% |
| 2011 Q2 | 20.25 Million USD | 4.86% |
| 2010 Q2 | 11.38 Million USD | -57.17% |
| 2010 Q4 | 11.26 Million USD | 5.1% |
| 2010 FY | 11.26 Million USD | -56.74% |
| 2010 Q1 | 26.58 Million USD | 2.14% |
| 2010 Q3 | 10.71 Million USD | -5.91% |
| 2009 Q3 | 17.31 Million USD | 230.11% |
| 2009 Q1 | 4.16 Million USD | 33.53% |
| 2009 Q2 | 5.24 Million USD | 26.0% |
| 2009 FY | 26.02 Million USD | 735.03% |
| 2009 Q4 | 26.02 Million USD | 50.36% |
| 2008 Q2 | 4.08 Million USD | -20.81% |
| 2008 Q4 | 3.11 Million USD | -10.89% |
| 2008 Q3 | 3.49 Million USD | -14.41% |
| 2008 Q1 | 5.16 Million USD | -17.12% |
| 2008 FY | 3.11 Million USD | -49.94% |
| 2007 Q2 | 8.33 Million USD | -16.74% |
| 2007 FY | 6.22 Million USD | -51.33% |
| 2007 Q1 | 10 Million USD | -21.79% |
| 2007 Q3 | 7.44 Million USD | -10.69% |
| 2007 Q4 | 6.22 Million USD | -16.32% |
| 2006 Q4 | 12.79 Million USD | -20.23% |
| 2006 Q2 | 15.12 Million USD | 19.81% |
| 2006 FY | 12.79 Million USD | 0.49% |
| 2006 Q3 | 16.03 Million USD | 6.01% |
| 2006 Q1 | 12.62 Million USD | -0.83% |
| 2005 Q4 | 12.73 Million USD | 13.93% |
| 2005 Q1 | 8.68 Million USD | -85.2% |
| 2005 Q3 | 11.17 Million USD | 0.07% |
| 2005 Q2 | 11.16 Million USD | 28.59% |
| 2005 FY | 12.73 Million USD | -78.3% |
| 2004 FY | 58.68 Million USD | 15.15% |
| 2004 Q3 | 52.31 Million USD | 0.0% |
| 2004 Q4 | 58.68 Million USD | 12.18% |
| 2003 FY | 50.96 Million USD | 442.58% |
| 2002 FY | 9.39 Million USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| America Great Health | 4.82 Million USD | -546.036% |
| Ampio Pharmaceuticals, Inc. | 2.37 Million USD | -1211.911% |
| Aridis Pharmaceuticals, Inc. | 38.92 Million USD | 19.924% |
| Biora Therapeutics, Inc. | 132.63 Million USD | 76.499% |
| Bio-Path Holdings, Inc. | 2.77 Million USD | -1021.662% |
| Better Therapeutics, Inc. | 23.84 Million USD | -30.74% |
| Calithera Biosciences, Inc. | 8.28 Million USD | -276.28% |
| Comera Life Sciences Holdings, Inc. | 9.97 Million USD | -212.516% |
| Gene Biotherapeutics, Inc. | - USD | -Infinity% |
| eFFECTOR Therapeutics, Inc. | 26.33 Million USD | -18.345% |
| Eloxx Pharmaceuticals, Inc. | 31.78 Million USD | 1.926% |
| Evelo Biosciences, Inc. | 69.43 Million USD | 55.106% |
| Evolutionary Genomics, Inc. | 7.94 Million USD | -292.306% |
| Finch Therapeutics Group, Inc. | 48.11 Million USD | 35.21% |
| Galera Therapeutics, Inc. | 157.32 Million USD | 80.187% |
| Innovation1 Biotech Inc. | 3.5 Million USD | -789.087% |
| Kiromic BioPharma, Inc. | 21.28 Million USD | -46.413% |
| Navidea Biopharmaceuticals, Inc. | 12.51 Million USD | -149.071% |
| NexImmune, Inc. | 5.08 Million USD | -513.092% |
| Orgenesis Inc. | 35.53 Million USD | 12.281% |
| Panbela Therapeutics, Inc. | 16.51 Million USD | -88.778% |
| Point of Care Nano-Technology, Inc. | 266.41 Thousand USD | -11600.211% |
| PaxMedica, Inc. Common Stock | 2.29 Million USD | -1258.017% |
| Scopus BioPharma Inc. | 7.45 Million USD | -318.154% |
| Sorrento Therapeutics, Inc. | 494.5 Million USD | 93.697% |
| Statera Biopharma, Inc. | 22.67 Million USD | -37.46% |
| TRACON Pharmaceuticals, Inc. | 10.91 Million USD | -185.606% |
| Trevena, Inc. | 48.26 Million USD | 35.413% |
| Vaxxinity, Inc. | 30.94 Million USD | -0.734% |
| Vaccinex, Inc. | 5.94 Million USD | -424.588% |
| Vicapsys Life Sciences, Inc. | 1.96 Million USD | -1483.621% |
| Viracta Therapeutics, Inc. | 38.37 Million USD | 18.768% |
| ZIVO Bioscience, Inc. | 2.76 Million USD | -1028.747% |